London (Reuters) – Britain will promote the use of
new medicines and allocated $ 280 million to carry
modern technologies to the market, under a reform package
designed to return to the country more attractive for the
large companies pharmaceutical.
Prime Minister David Cameron wants to use the funds for
promote the science of life, that British industry
invoice 50 billion pounds, according to the text of
a speech that will be issued Monday.
“The crucial and fundamental to that we are doing is to open
“
NHS (national health service) to new ideas. “The goal is
NHS work elbow to elbow with the industry as the most
rapid body that adopts new ideas in the world, acting as
large magnet to attract innovations (…) from laboratories
and meeting rooms up hospital beds”, will tell
Cameron.
Laboratories have been complaining for years that great
Britain used to be slow in the adoption of new medicines and the
use them in the NHS, of financing State.
The Minister of science, David Willetts, told the BBC radio:
“Above all, would have a clearer path from the idea in the
“
laboratory research with public support, to the
application in the patient in the NHS. “This is the way to
the business grow into the future and, of course, also
is the best thing for patients”.
Part of the project designed by Cameron, nicknamed “Fund
“”
Catalyst biomedical”, will be open to universities and
small and medium-sized enterprises, and establish a “scheme of
“”
early access” which severely ill patients
you can use new drugs up to a year before that they are
fully authorized.
“Patients are having to wait too long for
“
new medicines due to the extensive and extremely expensive
“
process to obtain full regulatory approval”, said
Richard Barker, director of the Center for the acceleration of the
Medical innovations, to be consulted on the announcement of the
Government.
“Health systems eventually have to pay these
“
costs in the price of new products. “It makes sense that
Great Britain, with its strengths in research, their
respectable regulators and major investment in Sciences of
life, take the lead”, added.
Part of the new plans will allow you to share the
patients and other NHS data records with the
companies in the sector, a measure that some critics fear that
compromise the confidentiality of the patient.
But Cameron argumentará in his speech to offer to the
researchers of the companies in the private sector access to the
information from the NHS will be provided the development and testing of
new drugs and treatments.
Great Britain is heavily dependent on the companies
pharmaceutical for the success of the production and the industry has been
been under pressure in recent years, which led to
make cuts.
A decision in February, the largest laboratory in the world,
Pfizer closed its research and Development Center in
Sandwich, England, and the consequent loss of 2,000 jobs
work, was a sign of vulnerability British.
Income from investment in new research
drugs fell almost 30 per cent last year in the
12 largest pharmaceutical companies in the world, what
highlights the dilemma of productivity facing the sector, according to
a study by Deloitte and Thomson Reuters of the month past.
